Puma Biotechnology (PBYI) Invested Capital (2010 - 2026)

Puma Biotechnology has reported Invested Capital for 17 years, with the latest figure at $139.7 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 1.92% year-over-year to $139.7 million; the trailing twelve-month figure through Mar 2026 stood at $139.7 million (down 1.92% YoY), and the FY2025 full-year result was $152.9 million, up 11.21% from the prior year.
• Invested Capital for Q1 2026 stood at $139.7 million, down from $152.9 million in the prior quarter.
• The five-year high for Invested Capital was $152.9 million in Q4 2025, with the low at $7.1 million in Q1 2022.
• Historically, Invested Capital has averaged $85.5 million across 5 years, with a median of $93.8 million in 2024.
• The largest YoY upside for Invested Capital was 983.4% in 2022 against a maximum downside of 81.77% in 2022.
• Puma Biotechnology's Invested Capital stood at $21.6 million in 2022, then soared by 304.66% to $87.4 million in 2023, then soared by 57.2% to $137.5 million in 2024, then grew by 11.21% to $152.9 million in 2025, then decreased by 8.61% to $139.7 million in 2026.
• The last three Invested Capital figures came in at $139.7 million (Q1 2026), $152.9 million (Q4 2025), and $149.0 million (Q3 2025), per Business Quant data.